“Both VX-150 and VX-128 represent an innovative new approach to the treatment of pain, and we are encouraged to now have positive proof-of-concept data from two studies of VX-150 that demonstrate for ...

-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...

2025年3月28日，Vertex Pharmaceuticals宣布终止其第二代1型糖尿病（T1D）细胞疗法VX-264的研发，这一消息无疑为糖尿病治疗领域的创新尝试蒙上了一层阴影。 尽管如此，Vertex并未放弃对糖尿病治疗的探索，其另一款疗法VX-880（zimislecel）仍在积极推进中，并已进入III期 ...

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -Global ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of ...